<DOC>
	<DOCNO>NCT02034981</DOCNO>
	<brief_summary>This biology driven , trans-tumoral , multicentric phase II trial assess efficacy safety target agent crizotinib monotherapy 23 cohort patient identify activate molecular alteration crizotinib target gene . A cohort define pathology crizotinib-target alteration ( eg gastric cancer MET amplification ) . For cohort two-stage design implement . In situation expect accrual allow sufficient number patient accrue , alpha beta error fix 10 % . However , rare disease , inflammatory myofibroblastic tumor ( IMT ) , neuroblastoma , glioblastoma , rhabdomyosarcoma ( RMS ) , anticipated target number may achievable reasonable timeframe ; cohort , alpha beta error fix 15 % . Consequently three different statistical design priori consider accord expect response rate incidence .</brief_summary>
	<brief_title>Phase 2 Study Assessing Efficacy Safety Crizotinib Patients Harboring Alteration ALK , MET ROS1</brief_title>
	<detailed_description>Twenty cohort identify , cohort define [ one pathology , one target alteration ] [ gastric cancer MET amplification ( 6 % ) ] . One cohort dedicate miscellaneous , rare pediatric disease identify INCa platform pan-genome program ( e.g . MOSKIDO , IGR ) recruit 10 patient . Two cohort dedicate couple disease harbour least one specific alteration one crizotinib target , different list , e.g . AXL gene , arise pan-genome trial . 1 . ALCL , adult child , ALK-translocated 2 . Colorectal cancer , adult , ALK-translocated 3 . Colorectal cancer , adult , MET amplify 4 . Colorectal cancer , adult , MET mutate 5 . NSCLC , adult , MET amplify 6 . NSCLC , adult , ROS1-translocated 7 . Breast cancer , adult , ALK-translocated 8 . Gastric cancer , adult , MET amplify 9 . Cholangiocarcinoma , adult , ROS1-translocated 10 . Ovarian cancer , adult , MET amplify 11 . Clear cell renal cell carcinoma , adult , ALK-translocated 12 . Clear cell renal cell carcinoma , adult , ALK-amplified 13 . Papillary renal cell carcinoma , adult , MET mutate ( + MET amplify ) 14 . Hepatocarcinoma , adult , MET amplify 15 . Neuroblastoma , adult child , ALK-amplified + ALK mutate 16 . IMT , adult child , ALK-translocated 17 . Rhabdomyosarcoma ( alveolar embryonal ) , adults child , ALK-amplified 18 . Glioblastoma , adult , MET amplify . This cohort open amendment 19 . Anaplastic thyroid cancer , adult , ALK mutate 20 . Thyroid cancer ( follicular + medullary + papillary ) , adult , MET mutate 21 . Miscellaneous rare pediatric disease associate least one specific alteration one crizotinib target , different list 22 . One another pathology associate least one specific alteration one crizotinib target , different list . 23 . One another pathology associate least one specific alteration one crizotinib target , different list .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<mesh_term>Crizotinib</mesh_term>
	<criteria>Inclusion : Male female ≥ 1 year age unresectable locally advanced metastatic malignant tumor histological type ( NSCLC ALK translocation ) amenable validate therapeutic option . ( pediatrics relapse first wellconducted standard treatment situation without standard treatment survival &lt; 10 % ) . one proven specific alteration among ALK , MET , RON ROS1 gene determine primary and/or metastatic lesion Measurable disease accord RECIST 1.1 For patient primary cerebral tumor ( adult child ) , measurable disease define bidimensional measurement : two perpendicular diameter least 10 mm CT MRI scan , outside previously radiate field within last 3 month , observe pseudoprogression hematologic function ( ANC ≥ 1.0x109/L , platelet ≥ 75x109/L , platelet ≥ 50x109/L ALCL bone marrow involve ; platelet ≥ 100x109/L primary secondary cerebral tumor ; Hb ≥ 8g/L ) , renal function ( creat cl ≥ 50 mL/min Cockcroft Gault ) hepatic function ( serum bilirubin ≤ 1.5x ULN unless due Gilbert 's syndrome ; ASAT ALAT ≤ 5x ULN liver metastasis ≤ 3x ULN liver metastasis advance fibrosis ( FibroTest &gt; 0.48 ) ≤ 3x ULN without liver metastasis ) normal value calcium , magnesium potassium level able swallow retain oral medication ECOG Performance Status 0 2 , Karnofsky scale &gt; 50 % Lansky Play scale ( &lt; 12 year ) &gt; 50 % , ( CNS tumor , neurological deficiency due disease ) Life expectancy ≥ 3 month Exclusion : NSCLC patient ALK translocation Patient eligible clinical trial anticancer drug ( include crizotinib ) target molecular alteration open accrual France . alteration limit overexpression ALK , MET , RON , ROS1 crizotinibtarget . Only patient ALCL eligible ALK positive immunohistochemistry Patients primary secondary central nervous system disease Previous treatment crizotinib Major surgery tumor embolization within 4 week minor surgery within 2 week prior initiation study drug . Brain surgery exclude within 4 week prior start crizotinib primary secondary cerebral tumor Patients concurrent severe and/or uncontrolled medical disease could compromise participation study , , limit : Within 3 month prior start study treatment : myocardial infarction , severe/unstable angina , coronary/peripheral artery bypass graft , cerebrovascular accident include transient ischemic attack Ongoing congestive heart failure Congenital long QT syndrome Heart rate ≤ 45 beats/minute Ongoing cardiac dysrhythmias NCI CTCAE Grade ≥2 , uncontrolled atrial fibrillation grade , QTcF interval &gt; 470 msec For patient cerebral disease ( primary secondary ) : uncontrolled hypertension [ define SBP ≥ 140 mmHg DBP ≥ 90mmHg ] extensive disseminated/bilateral know presence Grade 3 4 interstitial fibrosis interstitial lung disease , include pneumonitis , hypersensitivity pneumonitis , interstitial pneumonia , interstitial lung disease , obliterative bronchiolitis , pulmonary fibrosis , prior radiation pneumonitis Spinal cord compression unless treat patient attain good pain control stable recover neurologic function Carcinomatous meningitis leptomeningeal disease HIVpositive , active hepatitis A , B C , latent hepatitis B C , uncontrolled infection Other severe acute chronic medical psychiatric condition , end stage renal disease hemodialysis laboratory abnormality For patient cerebral disease , detection MRI CTscan real arteriovenous malformation , untreated intracranial aneurysm , cavernous angioma , amyloid angiopathy , new significant ( ≥ grade 2 ) intratumoral bleed microbleeds T2* weight MRI previous 14 day treatment initiation , recent untreated subdural effusion . Patients use nonsubstitutable drug potent CYP3A4 inhibitor , potent CYP3A4 inducer Patients use nonsubstitutable drug CYP3A4 substrates narrow therapeutic index Patients cerebral disease use antiplatelet drug anticoagulant agent eligible treatment stop 7 day day1 . Patients alter mental status psychological , familial , sociological geographical condition potentially hamper compliance Individual deprive liberty place authority tutor .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>metastatic unresectable locally advanced malignancy .</keyword>
	<keyword>genomic alteration .</keyword>
	<keyword>biological crizotinib target ( ALK , MET , ROS1 , RON , AXL ) .</keyword>
</DOC>